Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16140914 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Livingstone M, et al. (2005) Valosin-containing protein phosphorylation at Ser784 in response to DNA damage. Cancer Res 65, 7533-40 16140914
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T26-p - Chk2 (human) ▲
Orthologous residues
Chk2 (human): T26‑p, Chk2 iso12 (human): T26‑p, Chk2 (mouse): S29‑p, Chk2 (rat): S28‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  VCP recognized by Chk2 T26/S28 antibody
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
doxorubicin increase

S28-p - Chk2 (human) ▲
Orthologous residues
Chk2 (human): S28‑p, Chk2 iso12 (human): S28‑p, Chk2 (mouse): P31‑p, Chk2 (rat): S30‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  VCP recognized by Chk2 T26/S28 antibody
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
doxorubicin increase

S784-p - VCP (human) ▲
Orthologous residues
VCP (human): S784‑p, VCP (mouse): S784‑p, VCP (rat): S784‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioma
 Relevant cell lines - cell types - tissues:  HeLa (cervical), M059J (glial), M059K (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  VCP recognized by Chk2 T26/S28 antibody
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE DNAPK (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
doxorubicin increase
bleomycin increase
wortmannin bleomycin inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Comments:  localizes to DNA double-strand breaks


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.